TreeTopp: Randomized Phase 2 Study of Varlitinib plus Capecitabine versus Placebo in Second-Line Advanced or Metastatic BTC

Web Exclusives — May 28, 2020

Varlitinib is a reversible small-molecule pan human epidermal growth factor receptor (HER) inhibitor with low nanomolar potency against HER1 (EGFR), HER2, and HER4.

TreeTopp1 was a global, multicenter, double-blind, phase 2 study in which patients with biliary tract cancer (BTC) who progressed after first-line therapy that included ≥6 doses of gemcitabine, with radiographically measurable disease based on RECIST v1.1, ECOG PS 0 or 1, and albumin ≥3 g/dL. The patients were randomized (1:1) to varlitinib (V) (300 mg twice daily) plus capecitabine (C) (1000 mg/m2 twice daily 14 days on/7 days off) (V + C) or placebo plus capecitabine (P + C). The dual primary end points were objective response rate (ORR) and progression-free survival (PFS), defined as the time from randomization to radiologic progression assessed by independent central review. Secondary end points included overall survival (OS).

A total of 127 patients were randomized (V + C, n = 64; P + C, n = 63). The odds ratio for ORR with V + C versus P + C was 2.278 (9.4% vs 4.8%; P = .42), the hazard ratio (HR) for PFS for V + C versus P + C was 0.90 (median PFS, 2.8 vs 2.8 months; P = .63), and the HR for OS for P + C versus V + C was 1.11 (median OS, 7.8 vs 7.5 months; P = .66). Although not powered to evaluate subgroup interactions, in a subgroup analysis, V + C showed PFS benefit versus P + C in 2 subgroups: gallbladder cancer (HR, 0.55), median PFS (2.9 vs 1.6 months); and females (HR, 0.59), median PFS, 4.1 versus 2.8 months. There was no PFS benefit for V + C versus P + C among males and non-gallbladder cancer patients. Toxicities were generally balanced between arms apart from a slightly higher incidence of hyperbilirubinemia, diarrhea, and fatigue in the V + C versus P + C arm. Grade 3/4 toxicities were reported in 66% and 59% of patients in the V + C and P + C arms, respectively.

Based on the interim data as of July 15, 2019, the authors concluded that although there was no benefit for V + C for ORR, PFS, or OS versus P + C in second-line advanced BTC, subgroup analysis suggested that patients with gallbladder cancer and female patients achieved a comparatively higher median PFS with V + C versus P + C. ClinicalTrials.gov number NCT03093870.

Reference

  1. Javle M, et al. ASCO 2020. Abstract 4597.

Related Items

Updated Results from the TOPAZ-1 Study of Durvalumab plus GemCis in Patients with Advanced BTC
2022 Year in Review: Cholangiocarcinoma
Updated data from the TOPAZ-1 study revealed improved median overall survival for the full patient population and no new safety signals.
Final Results from the FIGHT-202 Trial of Pemigatinib in Metastatic CCA
2022 Year in Review: Cholangiocarcinoma
Final analysis of the phase 2 FIGHT-202 trial demonstrated durable response and a tolerable safety profile for pemigatinib in patients with metastatic cholangiocarcinoma.
Results from the BilT-04 Study: First-Line GemCis with or without CPI-613 in Advanced BTCs
2022 Year in Review: Cholangiocarcinoma
The BilT-04 study revealed that the addition of CPI-613 to gemcitabine/cisplatin was well-tolerated with potential activity in patients with advanced biliary tract cancers.
Updated Results from the FOENIX-CCA2 Trial of Futibatinib in Patients with iCCA Harboring FGFR2 Fusions/Rearrangements
2022 Year in Review: Cholangiocarcinoma
Updated FOENIX-CCA2 trial results were found to be consistent with the primary analysis, indicating durable efficacy and continued tolerability of futibatinib in patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements.
Durvalumab plus GemCis in Advanced BTC: A New Standard-of-Care?
2022 Year in Review: Cholangiocarcinoma
Phase 3 TOPAZ-1 clinical trial established durvalumab plus gemcitabine/cisplatin as a viable first-line standard-of-care treatment regimen for advanced biliary tract cancer.
Efficacy and Safety of Nab-Paclitaxel plus Gemcitabine/Cisplatin in Korean Patients with Advanced Biliary Tract Cancers
2021 Year in Review: Cholangiocarcinoma
Real-world retrospective evidence from Korean patients with advanced biliary tract cancer indicates that efficacy and safety with nab-paclitaxel plus gemcitabine/cisplatin combination were consistent with those previously reported in clinical trials.
Role of ctDNA to Predict Risk for Recurrence Following Potentially Curative Resection of Biliary Tract and Pancreatic Malignancies
2021 Year in Review: Cholangiocarcinoma
Results of a pilot study demonstrate the feasibility of ctDNA testing and the prognostic value of ctDNA following potentially curative resection in patients with pancreatic/biliary tract malignancies.
Does Adjuvant Chemoradiation Benefit Patients with Lymph Node–Positive Biliary Tract Cancer? A Secondary Analysis of SWOG S0809
2021 Year in Review: Cholangiocarcinoma
Results of the secondary analysis of the SWOG S0809 trial indicate that nodal status did not impact survival outcomes achieved with adjuvant chemoradiation postresection in patients with extrahepatic CCA or gallbladder cancer.
Liposomal Irinotecan plus 5-Fluorouracil/Leucovorin or Gemcitabine/Cisplatin in Patients with Advanced Biliary Tract Cancer (NIFE Trial)
2021 Year in Review: Cholangiocarcinoma
The phase 2 NIFE study compared a liposomal irinotecan plus fluorouracil and leucovorin regimen with standard-of-care gemcitabine/cisplatin in patients with advanced biliary tract cancer.
Liposomal Irinotecan in Combination with 5-Fluorouracil and Leucovorin for Patients with Metastatic Biliary Tract Cancer After Progression on Gemcitabine plus Cisplatin: A Multicenter, Comparative, Randomized, Phase 2b Study (NIFTY)
2021 Year in Review: Cholangiocarcinoma
Results of the NIFTY trial demonstrated that liposomal irinotecan plus 5-fluorouracil and leucovorin significantly improved efficacy outcomes compared with 5-fluorouracil plus leucovorin alone in patients with biliary tract cancer who progressed on prior gemcitabine/cisplatin, with a manageable adverse event profile.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: